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There is an urgent need to develop effective therapies against hepatitis C virus with different modes of action
from limited options already available. In this issue, Montero and coworkers present a detailed study on using
peptide nanotubes to effectively block the entry of HCV into target cells.It is estimated that more than 170 million
people world-wide are infected with
hepatitis C virus (HCV), and a large
proportion of those infected may eventu-
ally develop acute and chronic hepatitis
and hepatocellular carcinoma (Alter,
1997). These devastating numbers con-
tinue to put pressure on the scientific
community to find a successful therapy
against HCV. To date, there has been
no general and effective solution. HCV
belongs to the Flaviviridae family and
comprises a single-stranded RNA
genome, which corresponds to a 3000
amino acid polypeptide that is processed
into at least 10 mature structural and
functional viral proteins. Today, we have
a very good understanding of the HCV
life cycle and factors that lead to viral
infections (Pawlotsky et al., 2007). The
infection process is initiated by the
attachment of the virus to the cell surface
and entry followed by the uncoating of
single-stranded RNA genome. Transla-
tion of HCV genome into polypeptide
and cleavage by NS3/NS4A protease
generates the viral proteins. The as-
sembly of these virions and maturation in
the ER lumen follows. After being trans-
ported to the cell surface, the virions are
released into circulation and undergo
postrelease maturation to become in-
fectious. Because our understanding of
several of these steps at the molecular
level, various new classes of anti-HCV
drugs are now being developed, such as
NS3/4A protease and NS5B polymerase
inhibitors.
Despite the fact that new therapies
based on combinations of pegylated
interferon with direct-acting antivirals
such as ribavirin are now used to treat
HCV patients, these drugs exhibit limited
efficacy and serious side effects (Gelmanand Glenn, 2011). Moreover, the dangers
associated with the emergence of resis-
tant variants, due to the inherent inac-
curacy of the RNA polymerase and the
selective pressures of antiviral drugs that
favor drug resistance, requires the search
for new therapies with unique modes of
action, improved efficacy, and toxicity
profiles. In this issue of Chemistry and
Biology, Montero and coworkers (2011)
report on a family of highly active cyclic
peptides that assemble to nanotubes
and specifically block the entry of all
tested HCV genotypes into target cells
at a post-binding step (Figure 1).
The Ghadiri group has pioneered the
development of a class of cyclic peptides
that is known to self-assemble in well-
defined nanotube supramolecular struc-
tures (Ghadiri et al., 1993). Cyclic peptides
contain an even number of alternating D-
and L-a-amino acid residues with ring-
shaped conformations. Under conditions
that favor hydrogen bonding, e.g., lipid
membranes, the donor and the acceptor
of the amide backbone functionalities on
either side of the ring are fully engaged in
internal hydrogen bond networks, which
assist in stacking these peptides to form
nanotube like ensembles. Since this
development, the Ghadiri group (Ashke-
nasy et al., 2006) has been engaged in
using these nanotubes for various appli-
cations such as converting them to bio-
materials with extended charge delocal-
ized states for potential use as optical
and electronic devices. Moreover, the
group was able to design these cyclic
peptides into antibacterial agents that
are capable of selectively targeting bacte-
rial membrane where they were shown to
exert antibacterial activity by self-assem-
bling and increasing the membrane per-
meability (Fernandez-Lopez et al., 2001).Chemistry & Biology 18, November 23, 2011 ªIn the current work, the utility of these
nanotubes is extended to combat HCV.
To achieve this, 144 sequences, known
to be nontoxic in HeLa cells, were
screened in a cell-based ELISA assay
and nine cyclic amphiphilic octapeptides
emerged as potential hits with EC50
between 8 to 16 mM. Studying the struc-
tural features that are required for antiviral
activity of these peptides has revealed
that the peptides are amphiphilic with
net neutral charge structures, the antiviral
activity is sequence dependant, and
the cyclic structure and supramolecular
assembly are required for the antiviral
activity. This has been supported by
several experiments such as preparing
the linear or the N-methylated analogs of
these peptides, which led to a significant
loss of the antiviral activity. Studying the
mode of action of these peptides indi-
cated that they are likely to interfere with
an early step of the infection without
altering the binding of the virus to the
target cell, but inhibiting a step in viral
entry downstream of cell binding. These
conclusions came in light of several
observations. For example, peptides
do not show any antiviral activity when
added after the virus already entered the
cell in the time-of-addition experiment,
and HCV-pseudotyped lentiviral particle
entry into Huh-7 cells was efficiently in-
hibited in a dose-dependent manner by
the peptide nanotubes. Importantly, these
peptides exhibited activity against all
the tested HCV genotypes and were
found to efficiently control viral spread in
cell culture.
The studies described by Montero
and coworkers (2011) represent another
remarkable and exciting application of
peptide nanotubes and open new front
in the fight against HCV. In the assembled2011 Elsevier Ltd All rights reserved 1347
Figure 1. The Use of Peptide Nanotubes as Potential Therapeutics against HCV
The peptides comprising eight amino acids of alternating D- and L-a-amino acid residues are prepared using solid phase peptide synthesis. Upon interacting with
cellular membranes, these peptides assemble into nanotubes and exert, in part, their antiviral activity by blocking the HCV entry to the cell. R1–R8, amino acid side
chains; —, a hydrogen bond within the nanotube.
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located on the outside surface of the
ensemble, which should allow their func-
tionalization without much interference
with the supramolecular structures. For
example, this could be useful to enhance
their drug-like properties and allow
specific labeling for a variety of mecha-
nistic studies. Moreover, due to their
relative ease of preparation and low
molecular weight, these peptide nano-
tubes could potentially boost the current1348 Chemistry & Biology 18, November 23,arsenal of antiviral compounds against
other existing infectious diseases.REFERENCES
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Using chemical approaches, Ma et al. in this issue of Chemistry & Biology identify mitochondrial complex III
as a specific positive regulator of autophagy. This study brings us a step closer to understanding the mech-
anism by which basal autophagy is coupled to cellular energy flux.Autophagy is a membrane trafficking
process leading to lysosomal degradation
of cytoplasmic components. This evolu-
tionarily conserved process serves two
fundamental functions (Mizushima, 2005;
Mizushima et al., 2008). First, the consti-
tutive, or basal, autophagy allows cells
to turnover long-lived proteins and organ-
elles, providing an important mechanismfor cellular maintenance. Second, auto-
phagy can be dramatically elevated in
response to stress conditions, in partic-
ular, nutrient deprivation. This allows cells
to mobilize internal resources for main-
taining cellular homeostasis during fluc-
tuations of external environment. How
nutrients and nutrient deprivation regulate
autophagy has been extensively investi-gated; however, much less is known
about the nature of basal autophagy.
One important question regarding
basal autophagy is whether it is a passive
repair process that responds to damaged
or dysfunctional long-lived proteins or
organelles, or if it is an active process
that preemptively turns over cytoplasmic
components. If the first scenario is true,
